Back to search

Article

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration <i>in vivo</i>

2021-10-27

Abstract excerpt

Proteasome-addicted neoplastic malignancies present a considerable refractory and relapsed phenotype with patients exhibiting drug-resistance and high mortality rates. To counter this global problem, novel proteasome-based therapies are being developed. In the current study we extensively characterize TIR-199, a syrbactin-class proteasome inhibitor derived from a plant virulence factor of bacterium Pseudomonas sy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ac42f486-141e-5751-b26c-4645b487fe37
DOI
10.1101/2021.10.27.466109
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration <i>in vivo</i>DOI 10.1101/2021.10.27.466109
Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity
Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effectsSemantic proximity
Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myelomaSemantic proximity
Enhancing c-MYC degradation via 20S proteasome activation induces <i>in vivo</i> anti-tumor efficacySemantic proximity
Structure-Based Design of β1i or β5i Specific Inhibitors of Human ImmunoproteasomesSemantic proximity
Molecular Mechanisms of Acquired Proteasome Inhibitor ResistanceSemantic proximity
Protein degradation: expanding the toolbox to restrain cancer drug resistanceSemantic proximity
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastomaSemantic proximity
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin LymphomaSemantic proximity
Targeting the ribosome to treat multiple myelomaSemantic proximity
The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer CellsSemantic proximity
Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceSemantic proximity
Select a neighboring publication to make it the new centre.